LFTs Introduction (What it is)
LFTs are blood tests that help assess how the liver is functioning.
They are commonly used in oncology to establish a baseline before treatment and to monitor safety during therapy.
LFTs can also support evaluation when cancer may involve the liver or when symptoms suggest liver or bile-duct problems.
The term “LFTs” usually refers to a panel of related lab values interpreted together, not a single test.
Why LFTs used (Purpose / benefits)
In cancer care, the liver matters because it processes many medications, helps regulate metabolism, and produces important proteins needed for normal body function. Many cancer treatments—including some chemotherapies, targeted therapies, immunotherapies, hormonal therapies, antifungals, and supportive medications—can affect the liver. In addition, cancers may spread (metastasize) to the liver, or cancers that start in the liver or bile ducts can directly disrupt liver function.
LFTs help clinicians:
- Detect possible liver injury early so treatment teams can reassess medication choices, dosing, or timing.
- Assess whether the liver is “handling” therapy from a safety and tolerability standpoint.
- Support diagnostic workups when patients have symptoms such as jaundice (yellowing of the skin/eyes), dark urine, itching, right-upper abdominal discomfort, nausea, or unexplained fatigue.
- Contribute to staging and treatment planning when liver involvement is suspected, alongside imaging and sometimes biopsy.
- Monitor trends over time, which is often more informative than a single result.
LFTs do not diagnose cancer by themselves. Instead, they provide clinical context that helps guide next steps in evaluation and care.
Indications (When oncology clinicians use it)
Oncology clinicians commonly order LFTs in situations such as:
- Baseline assessment before starting systemic therapy (chemotherapy, targeted therapy, immunotherapy, hormonal therapy)
- Routine monitoring during treatment cycles, especially for drugs with known liver-related toxicities
- Evaluation of symptoms that may reflect liver or bile-duct dysfunction (e.g., jaundice, itching, pale stools)
- Investigation of abnormal imaging findings in the liver or bile ducts
- Assessment of suspected liver metastases or primary liver/bile-duct cancers
- Preoperative workup for cancer surgery involving the abdomen, liver, pancreas, or bile ducts
- Planning and monitoring for radiation therapy when the liver is within or near the treatment field
- Monitoring in patients with pre-existing liver disease (e.g., viral hepatitis, fatty liver disease, cirrhosis) receiving cancer therapy
- Evaluation for treatment eligibility or dosing decisions when liver function is a key safety factor (varies by clinician and case)
Contraindications / when it’s NOT ideal
Because LFTs are standard blood tests, there are few absolute reasons not to perform them. However, there are important situations where LFTs may be not ideal as a stand-alone tool or where another approach may be needed:
- LFTs cannot confirm or rule out cancer on their own; abnormal results require clinical correlation and often imaging and/or biopsy.
- Non-cancer causes are common (medications, infections, alcohol use, muscle injury, fatty liver disease), so abnormal values may be misleading without context.
- A normal LFT panel does not exclude liver metastases or other liver pathology; some liver lesions do not change blood tests early.
- Difficulty obtaining blood (poor venous access, severe needle-related distress, or specific bleeding risks) may require modified approaches, though blood tests are still often feasible.
- Results can be influenced by recent treatments or conditions (e.g., dehydration, hemolysis during sample handling), requiring repeat testing or confirmation.
When LFTs are abnormal or unclear, clinicians may rely more heavily on imaging (ultrasound, CT, MRI), additional blood tests, medication review, and sometimes liver biopsy, depending on the clinical scenario.
How it works (Mechanism / physiology)
LFTs reflect different aspects of liver and bile-duct physiology. They are not a single “liver function” measurement; instead, they combine markers of cell injury, bile flow, and synthetic function (the liver’s ability to make proteins and process substances).
Common components include:
- ALT and AST (aminotransferases): Enzymes that can rise when liver cells (hepatocytes) are injured or inflamed. AST can also increase from non-liver sources such as muscle, so interpretation matters.
- Alkaline phosphatase (ALP) and sometimes GGT: Values that may rise with cholestasis (impaired bile flow) or bile-duct irritation/obstruction. In oncology, this pattern can appear with bile-duct compression, certain liver metastases, or medication effects. ALP can also come from bone.
- Bilirubin: A breakdown product processed by the liver and excreted in bile. Higher levels can cause jaundice and may signal impaired processing or bile-duct blockage.
- Albumin and prothrombin time (PT/INR): Markers more closely related to the liver’s protein synthesis and overall functional reserve. These can be influenced by nutrition, inflammation, blood thinners, and other conditions as well.
Onset and duration: LFT changes may appear within days to weeks after an injury or medication exposure, but timing varies by cause and treatment. Many abnormalities improve when the underlying cause resolves, but reversibility depends on what is driving the change (varies by clinician and case).
LFTs Procedure overview (How it’s applied)
LFTs are not a treatment procedure; they are a lab assessment tool used throughout the cancer care pathway. A typical workflow looks like this:
- Evaluation/exam: The oncology team reviews symptoms (e.g., nausea, itching, jaundice), medical history (including viral hepatitis or alcohol use), and current medications and supplements.
- Labs: Blood is drawn (often from a vein in the arm or from an existing central line, if present) and sent for a hepatic panel and/or broader labs (such as a comprehensive metabolic panel).
- Imaging/biopsy (when needed): If LFTs are abnormal or symptoms suggest liver/bile-duct disease, clinicians may order ultrasound, CT, or MRI. A biopsy may be considered in selected cases to clarify the diagnosis.
- Staging context: If cancer involvement of the liver is suspected or confirmed, results are integrated with imaging and pathology to support staging and prognosis discussions (varies by cancer type and stage).
- Treatment planning: LFTs may influence medication selection, dosing, timing, and supportive care planning. Some drugs have specific liver-related thresholds in their prescribing guidance.
- Intervention/therapy: Cancer treatment proceeds with appropriate monitoring. If LFTs rise, clinicians may reassess medications, evaluate for infection or obstruction, and consider additional tests.
- Response assessment: LFT trends are interpreted alongside symptoms and imaging. Improvement can suggest recovery from injury or improved bile flow, but it is not a direct measure of tumor response by itself.
- Follow-up/survivorship: LFTs may continue after treatment, particularly if prior abnormalities occurred or if ongoing medications warrant monitoring.
Types / variations
In clinical practice, “LFTs” can mean different test groupings depending on the setting:
- Hepatic function panel (liver panel): Typically includes ALT, AST, ALP, bilirubin (total and sometimes direct), and albumin; many labs also include total protein.
- Comprehensive metabolic panel (CMP): Includes some liver-related values (usually ALT, AST, ALP, bilirubin, and albumin) plus electrolytes, kidney markers, and glucose.
- Synthetic function add-ons: PT/INR is often ordered when liver synthetic function is a concern, or before procedures where bleeding risk matters.
- Monitoring-focused vs diagnostic-focused ordering:
- Monitoring-focused: Regular checks during systemic therapy to detect trends early.
- Diagnostic-focused: Expanded evaluation when abnormalities are found, potentially adding viral hepatitis tests, autoimmune markers, iron studies, or medication/toxin review (varies by clinician and case).
- Inpatient vs outpatient: Inpatients may have more frequent LFT monitoring due to acute illness, infections, biliary obstruction, or treatment complications. Outpatients commonly have LFTs drawn before scheduled treatments.
- Adult vs pediatric oncology: The same general principles apply, but reference ranges, dosing considerations, and causes of abnormal LFTs may differ by age and treatment protocols.
Pros and cons
Pros:
- Helps establish a baseline before cancer treatment starts
- Enables trend monitoring over time, which can be clinically meaningful
- Supports safer use of many cancer and supportive medications
- Can raise suspicion for biliary obstruction or significant liver inflammation that needs prompt evaluation
- Widely available, fast to obtain, and generally low burden for patients
- Useful in both outpatient and inpatient oncology settings
Cons:
- Not cancer-specific; abnormalities are common from non-cancer causes
- Normal results do not rule out liver metastases or other liver disease
- Interpretation can be complex because values may reflect liver, bile ducts, bone, muscle, nutrition, or medication effects
- A single abnormal value may be less informative than repeat testing and patterns
- Abnormal results can trigger anxiety and additional testing, even when the cause is temporary
- Reference ranges and clinical thresholds can vary by laboratory and clinical context
Aftercare & longevity
Because LFTs are tests rather than a treatment, “aftercare” mainly means what happens after results are available and how monitoring continues over time.
In oncology, what affects the clinical significance of LFTs and how long abnormalities persist often includes:
- Cancer type and stage: Liver involvement and bile-duct compression are more likely in some cancers than others, and patterns can differ (varies by cancer type and stage).
- Tumor biology and location: Lesions near major bile ducts may cause cholestasis and bilirubin elevation, while diffuse liver involvement may affect multiple values.
- Treatment exposure and intensity: Some drugs are more likely to raise liver enzymes, and combinations can complicate interpretation.
- Other medical conditions: Viral hepatitis, fatty liver disease, alcohol-associated liver disease, malnutrition, and infections can change LFTs and recovery time.
- Supportive care and medication burden: Antiemetics, antibiotics, antifungals, pain medications, and supplements may contribute to liver test changes in some situations.
- Follow-up consistency: Repeat testing and coordinated review help clinicians understand whether changes are improving, stable, or worsening.
- Rehabilitation and survivorship needs: Ongoing fatigue, appetite changes, and nutrition challenges can indirectly influence markers like albumin.
Clinicians typically interpret LFTs alongside symptoms, exam findings, imaging, and the full medication list, focusing on patterns over time rather than isolated results.
Alternatives / comparisons
LFTs are often used together with other tools, rather than replaced by them. Depending on the clinical question, common alternatives or complementary approaches include:
- Observation with repeat testing: If a mild abnormality is found without concerning symptoms, clinicians may recheck labs to confirm a trend (varies by clinician and case).
- Imaging (ultrasound, CT, MRI): Better for identifying structural problems such as liver masses, bile-duct dilation, or vascular changes. Imaging can be normal even when blood tests are abnormal, and vice versa.
- Tumor markers: Sometimes used in specific cancers, but they are not definitive and do not replace LFTs for assessing liver injury or bile flow.
- Viral hepatitis testing and other targeted labs: Important when inflammation is suspected or when immunotherapy or certain chemotherapies are planned.
- Liver biopsy: Provides tissue diagnosis and can clarify the cause of abnormalities (e.g., cancer involvement vs drug-related hepatitis), but it is invasive and not always necessary.
- Treatment comparisons (contextual): LFTs can influence whether a clinician prefers one systemic therapy over another or adjusts dose/schedule. They do not directly compare “surgery vs radiation vs systemic therapy,” but they can affect eligibility and safety planning for each option.
- Clinical trials vs standard care: Trials often require specific baseline LFT criteria and close monitoring schedules. Standard care monitoring may be similar but varies by regimen and institution.
LFTs Common questions (FAQ)
Q: What do LFTs usually include?
LFTs commonly include ALT, AST, ALP, bilirubin, and albumin, and sometimes total protein. Many clinicians also consider PT/INR when they need a clearer picture of liver synthetic function. The exact panel depends on the lab and the clinical situation.
Q: Are LFTs used to diagnose cancer?
No. LFTs can suggest liver or bile-duct stress, but they do not diagnose cancer and are not specific to malignancy. If LFTs are abnormal, clinicians usually interpret them alongside symptoms, medication history, and imaging.
Q: Do LFTs indicate whether cancer has spread to the liver?
They can be abnormal with liver metastases, but they can also be normal even when metastases are present. Imaging is typically the main tool for identifying and characterizing liver lesions. LFTs add supportive information about how the liver is functioning.
Q: Are LFTs painful, and do they require anesthesia?
LFTs are performed from a standard blood draw, which may cause brief discomfort at the needle site. Anesthesia is not used for routine blood tests. Some patients have bruising or soreness afterward.
Q: Do I need to fast before LFTs?
Fasting is not always required for LFTs alone, but labs are often bundled with other tests (like lipid panels) that may require fasting. The ordering team or lab instructions typically specify preparation. If instructions are unclear, patients usually ask the care team for clarification.
Q: How long does it take to get results, and how long are they “valid”?
Turnaround time depends on the facility, but results are often available relatively quickly. How long results remain clinically useful depends on what is happening medically—values can change during illness or treatment. In oncology, clinicians frequently rely on recent labs and trends rather than older single results.
Q: What side effects or risks are associated with LFT testing?
The main risks are those of a blood draw: bruising, mild bleeding, lightheadedness, or rarely infection at the puncture site. People on blood thinners or with low platelets may bruise more easily, so staff may use added pressure after the draw. These are general considerations and vary by individual circumstances.
Q: Can cancer treatment raise LFTs even if the liver is otherwise healthy?
Yes. Some systemic therapies and supportive medications can irritate the liver or affect bile flow, leading to temporary or persistent changes in LFTs. Interpretation depends on the pattern of abnormalities, timing, symptoms, and other possible causes (varies by clinician and case).
Q: Will abnormal LFTs change my treatment plan?
They can. Depending on severity and cause, clinicians may repeat labs, review medications, order imaging, adjust dosing, pause a drug, or choose an alternative regimen. Decisions depend on cancer type, urgency of treatment, and the overall clinical picture.
Q: What do LFTs mean for fertility or pregnancy planning during cancer care?
LFTs do not directly measure fertility. However, liver function can influence which medications are considered appropriate and how they are dosed, which may indirectly affect broader treatment planning. Fertility and pregnancy-related decisions in oncology are individualized and depend on diagnosis and treatment options (varies by clinician and case).
Q: How much do LFTs cost?
Costs vary widely based on location, insurance coverage, and whether testing is done in a hospital, clinic, or external lab. Panels bundled with other labs may be billed differently than stand-alone tests. For accurate expectations, patients typically ask their care team or the billing office for local guidance.